

Additional File 1 for:

The *C. elegans* 3'-UTRome V2: an updated genomic resource to study 3'-UTR biology

Steber HS ^{1, 2}, Gallante C³, O'Brien S², Chiu P.-L⁴, Mangone M*^{1, 2}.

¹Molecular and Cellular Biology Graduate Program, School of Life Sciences 427 East Tyler Mall Tempe, AZ 85287 4501.

²Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute at Arizona State University, 1001 S McAllister Ave, Tempe, AZ, USA

³Barrett, The Honors College, Arizona State University, 751 E Lemon Mall, Tempe, AZ 85281

⁴Center for Applied Structural Discovery, The Biodesign Institute at Arizona State University, 1001 S McAllister Ave, Tempe, AZ, USA

*To whom correspondence should be addressed. Tel: +1(480) 965-7957; Fax: +1(480) 965-3051; Email: mangone@asu.edu

Present Address: Marco Mangone, Arizona State University, Biodesign Institute Building A, 1001 S McAllister Ave, Tempe, AZ 85281 USA

This PDF includes:


- **Figures S1-S14**
- **Supplemental Materials and Methods**

Table of Contents

Additional File 1


Figure S1: Protein alignment of members of the CPC complex in five species	3
Figure S2: Results of the RNAi experiments of the <i>C. elegans</i> CPC.....	14
Figure S3: Bioinformatic pipeline used in this study	15
Figure S4: Comparison with Tourasse et al., 2017.....	16
Figure S5: PAS site usage in genes with multiple 3'-UTR isoforms.....	17
Figure S6: Detection of the PAS element in genes lacking a canonical AAUAAA hexamer.....	18
Figure S7: GO term analysis for genes with 1, 2 or 3 3'-UTR isoforms	19
Figure S8: Detection of the 'UGUA' element in <i>C. elegans</i> 3'-UTRs.....	20
Figure S9: Detection of enriched elements in 3'-UTRs of genes with 2 3'-UTR isoforms.....	21
Figure S10: Nucleotide binding site of the human CPSF160-WDR33-CPSF30 complex	22
Figure S11: <i>In vivo</i> cleavage assay for M03A1.3	23
Figure S12: <i>In vivo</i> cleavage assay for Y106G6H.9.....	24
Figure S13: <i>In vivo</i> cleavage assay for <i>ges-1</i>	25
Figure S14: miRNA target analysis in genes with 2 3'-UTR isoforms which either gain or lose a miRNA binding site.....	26
Supplemental Materials and Methods:	27

CPSF-1 (CPSF1)



Supplemental Figure S1: Protein alignment of members of the CPC complex in five organisms. Amino acid sequence alignment for the members of the CPC from five organisms using Clustal Omega Multiple Sequence Alignment. Conserved domains produced under the Batch Conserved Domain Search on NCBI are represented by the highlighted regions of each figure. Known domains determined from previously published literature are outlined.


CPSF-2 (CPSF2)



Metallo-beta-lactamase domain (Mandel et al., 2006)

Beta-CASP domain (Mandel et al., 2006)

CPSF-3 (CPSF3)



Metallo-beta-lactamase domain (Mandel et al., 2006)

Beta-CASP domain (Mandel et al., 2006)


Bridging ligand to Zinc atoms (Mandel et al., 2006)

Ligands to Zn1 (Mandel et al., 2006)


Ligands to Zn2 (Mandel et al., 2006)


General acid for catalysis (Mandel et al., 2006)

CPSF-4 (CPSF4)



FIPP-1 (FIP1L1)



 N-terminal domain, contacts CPSF160 and CPSF30 (Clerici et al., 2017)

 WD40 repeats, contact U3 and A6 of PAS (Clerici et al., 2017)

Schematic diagram of the CSTF1 protein structure. The protein is represented as a linear sequence from N-terminus (N) to C-terminus (C). It features a green rectangular domain labeled 'WD40 Domain' and a larger orange oval domain labeled 'CSTF1 Dimer'.


[illegible]

☐ N-terminal domain (Yang et al., 2018)

Worm	MMSGGYKSSGVGNDRSQRSVFVGNISYDVS EDTIRISFSAKGNVLSIKMVDRETGPKKG	60	Worm	-MGHPAPQYQGYN-----GQVAPQYQYK---PPFQQQP	27
Fly	--MADKAGQSSIMDKSMRSVFVGNIPYEATEEKLKEI SEVGPVLSKLIVDREGSGPKG	58	Fly	GR--GMDQDLRASLPNNPV-----PFLMDP	29
Human	--MAGLTVRDPADVRSLSRVFVGNIPYEATEEQLKDI SEVGPVSVFRLIVDRETGPKG	58	Human	PMQDPRAAMQRGSLPANVPTRGLLGDAAPNPGGTLISVTGEVEPAGYLG---PQHG	33
Mouse	--MAGLTVRDPADVRSLSRVFVGNIPYEATEEQLKDI SEVGPVSVFRLIVDRETGPKG	58	Mouse	PMQDPRAAMQRGSLPANVPTRGLLGDAAPNPGGTLISVTGEVEPRALYGPFPFPFQHG	35
Rat	--MAGLTVRDPADVRSLSRVFVGNIPYEATEEQLKDI SEVGPVSVFRLIVDRETGPKG	58	Rat	PMQDPRAAMQRGSLPANVPTRGLLGDAAPNPGGTLISVTGEVEPRALYGPFPFPFQHG	35
	.. * : * * * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : *			.. * : * * * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : *	
Worm	YGFIEFDDQITAEVARNLNGVLSGRILNVDSAGAGNMEEFSGSSNAPAVEENPYG	120	Worm	PVQMRPFVQQ-----	28
Fly	YGFCEYQDQETALSMRNLNGVEIGRTLRVDNACTKSRMEMQQL-LQG-PQVENVG	116	Fly	---ARAQMPQQQGGVQPAAPYPSDPDRQPMDR---LR---	33
Human	YGFCEYQDQETALSMRNLNGREFSGRLVDNAASEKNKEELKSL-CTGAPVIESPYG	117	Human	PMNHVPHVCEGRGPPHLELGGPLPEFPRFLMAEPGPMLDQSGPLDQGRGDRPGIDARG	39
Mouse	YGFCEYQDQETALSMRNLNGREFSGRLVDNAASEKNKEELKSL-CTGAPVIESPYG	117	Mouse	PMNHVPHVCEGRGPPHMDRGGPLAEPRFLMAEPGPMLDQSGPLDQGRGDRPGIDARG	41
Rat	YGFCEYQDQETALSMRNLNGREFSGRLVDNAASEKNKEELKSL-CTGAPVIESPYG	117	Rat	PMNHVPHVCEGRGPPHMDRGGPLAEPRFLMAEPGPMLDQSGPLDQGRGDRPGIDARG	41
	.. * * * : * : * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *			.. * * * : * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *	
Worm	ECDAKGAPEIRISQTVASLAEPEKFMELMKQLGSELSKNPSELAKHPLVEHPQIAVAVLQAA	180	Worm	---	28
Fly	PCPEQDAPELITKTVASLPEQFMELMKQLKVLCSVSEARQMLNLQPLAYALLQAV	176	Fly	---AGCPGQ	35
Human	SISPEDAPESISKAVASLPPEQFMELMKQLKVLCSVSEARQMLNLQPLAYALLQAV	177	Human	MEARAMEARGLDARGLEAREAMEAREAMEAREAMEAREAMEAREMEARGMDTRGVPVGP	40
Mouse	SISPEDAPESISKAVASLPPEQFMELMKQLKVLCSVSEARQMLNLQPLAYALLQAV	177	Mouse	MEARAMEARGLDARGLEAREAMEAREAMEAREAMEAREAMEAREMEARGMDTRGVPVGP	47
Rat	SISPEDAPESISKAVASLPPEQFMELMKQLKVLCSVSEARQMLNLQPLAYALLQAV	177	Rat	MEARAMEARGLDARGLEAREAMEAREAMEAREAMEAREAMEAREMEARGMDTRGVPVGP	47
	.. * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *			.. * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *	
Worm	VMRIVDPQTLGLLRHNKAATLTPFHTN-----P	209	Worm	QAP-PGGIPFAPPTTQQQ-----QAA---AQQLSRGAS---HGVFLSDAS	29
Fly	VMRIVDPQQAQGLFIKIANMGPVGLGNNPQC-----PGNH---TMMGQQVV---PQQQ	223	Fly	RGPIPSGQ---GFSRINMNVPGQSRQVVPQCGMQGQASGSGQPGGFSFGSQVTFQ	50
Human	VMRIVDPALIKILHRTNITPTLIGNP-----DAQSLGM	213	Human	RGPMPSGIQ---GNPMMNGVAPVQGSQVVPVQCGMQGQASGSGQPGGFSFGSQVTFQ	53
Mouse	VMRIVDPALIKILHRTNITPTLIGNP-----DAQSLGM	237	Mouse	RGPMPSGIQ---GNPMMNGVAPVQGSQVVPVQCGMQGQASGSGQPGGFSFGSQVTFQ	53
Rat	VMRIVDPALIKILHRTNITPTLIGNP-----DAQSLGM	237	Rat	RGPMPSGIQ---GNPMMNGVAPVQGSQVVPVQCGMQGQASGSGQPGGFSFGSQVTFQ	53
	***** : * * : * : . : *			***** : * * : * : . : *	
Worm	--QGAPPVQQ-----QMPMPKKPTFA---HPGFSNGPMPG-----PMGPG	247	Worm	EQPQIAELLVMQVQLSEHDLQNLPGADREKIITELRQQLKKNVK---	336
Fly	---VQIQQQAQAPQMPPV---PGCFGFAVHPNDILRHVPGGPMMDPRM	271	Fly	DQEKAALIMOVQLSDQEQIAQPSQGRSVIHLKEQIAKSTQR---	419
Human	HVHGAPPLMQSMQSGPGVPAPGQMAAIVTGPCGSLAPAGMGQACVQMGQSGPVSMERGQV	273	Human	DHEKAALIMOVQLTADQIAMLPPEQRGISILILKEQIKSTGAP	553
Mouse	HVHGAPPLMQSMQSGPGVPAPGQMAAIVTGPCGSLAPAGMGQACVQMGQSGPVSMERGQV	273	Mouse	DHEKAALIMOVQLTADQIAMLPPEQRGISILILKEQIKSTGAP	580
Rat	HVHGAPPLMQSMQSGPGVPAPGQMAAIVTGPCGSLAPAGMGQACVQMGQSGPVSMERGQV	297	Rat	DHEKAALIMOVQLTADQIAMLPPEQRGISILILKEQIKSTGAP	575
	.. * : * * * : *			.. * : * * * * * : * : * : * : * : * : * : * : * : *	

☐ C-terminal domain (Yang et al., 2018)

[illegible]

 HAT-N Domain (Bai et al., 2007)

☐ HAT-C Domain that interacts with CPSF160 (Bai et al., 2007)

N

C

 Nudix domain (Yang et al., 2011) CFIm68 and CFIm59 tethering site (Zhu et al., 2017)

N

PABP-1234

C


RRM domain (Yang et al., 2011, Martin et al., 2010)
 RS/RD/RE region (Yang et al., 2011)

Pro/Gly-rich region (Yang et al., 2011)

[illegible]

☐ Residues that crosslink to PCF-11 (Schäfer et al., 2018)

RBPL-1 (RBBP6)



PAP-1 (PAP1N)


N		PAP Central	PAP RNA Binding	C	
Worm	-----MSATEKDKTPLLQVSPISLAHPDSKDIAQTLLIRTLKPGVS	44	Worm	AEHA---FTLQLTNEIQFNTNVELQASNVKIGIPNCQVQIDMFYVKRNSLIQVISAAD	499
Fly	MWNSEPTHRQHNGSTGGPPAKQLDMSAISLAEPKPDQRTDELKGLSEPNV	60	Fly	ER---SENANVDLTESIQNFTEHVMHGVNIMKLEEG--MTIDARHVKKQLSLYLDSD	530
Human	-----MPFVTTQGSQQTQPPQHRHYGITSPLSAAKETDCVLTQKLIBTLKPGVF	52	Human	KKTENSENLVDLTIDYIQSFDTTVYRQAINSKMFELD--MKIAMHVKKQLHLQLPSHV	501
Mouse	-----MPFVTTQGSQQTQPPQHRHYGITSPLSAAKETDCVLTQKLIBTLKPGVF	52	Mouse	KKTENSENLVDLTIDYIQSFDTTVYRQAINSKMFELD--MKIAMHVKKQLHLQLPSHV	501
Rat	-----MPFVTTQGSQQTQPPQHRHYGITSPLSAAKETDCVLTQKLIBTLKPGVF	52	Rat	KKTENSENLVDLTIDYIQSFDTTVYRQAINSKMFELD--MKIAMHVKKQLHLQLPSHV	501
	* : : : * * * * * * * * * * : : : * : : *			* : : : * * * * * * * * * * : : : * : : *	
Worm	EPKEETEQRMEVLNINLVKEMVKNVTAM-KIPNGGVNAGGKLTFTGYSRLGVNSSGA	103	Worm	LRRGRNKKVVPVIAITNTSVSSETPRSVVRTTSSSVPTTPTGLAAPTPLASVSATNEP	559
Fly	ESQDELNHRMEILAKINTLVQWVKEISVSKNMPESAERKLGKIIYTFGYSRLGVNKGGA	120	Fly	LKRERKSMESHNNFNNTLLAN--RKRLSTELAQSO-DPLPP-GQQ-----PSSGN---	576
Human	EEEEELQRRILLGKLNHLVKEWIREISESKNLPQSVIENVGGKIFTGYSRLGVNKGGA	112	Human	LQKKKKHSTEGVKLT--ALNDSLDLSMDSDNSMSVPSPT-SAT-KTSPLNSSGSS---	553
Mouse	EEEEELQRRILLGKLNHLVKEWIREISESKNLPQSVIENVGGKIFTGYSRLGVNKGGA	112	Mouse	LQKKKKHSTEGVKLT--ALNDSLDLSMDSDNSMSVPSPT-SAT-KTSPLNSSGSS---	553
Rat	EEEEELQRRILLGKLNHLVKEWIREISESKNLPQSVIENVGGKIFTGYSRLGVNKGGA	112	Rat	LQKKKKHSTEGVKLA--ALNDSLDLSMDSDNSMSVPSPT-SAT-KTSPLNSSGSS---	553
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	
Worm	DIDTLAVPRHIDRSDFTSFKEMLNNDPNUTELHGVRAFPVPMKLYSGVELDILFAR	163	Worm	DSTTNGTPLSKRR-SMDEES-----STTVTSQISDESVPKRTKTRDDTLEENRVMV	609
Fly	DIDALCVAPRNIERTDYFQSFEVLKQPEVTECRSVEEAFVPMKLYSGVELDILFAR	180	Fly	RGDRSGAKIQRLSDSLTEENSASSDMGAGTPTTPTAQLSAPSKSSGKNGSE---	630
Human	DIDALCVAPRHVDRSDFTSFYDKLQEEVKDLRAVEAFVPMKLYSGVELDILFAR	172	Human	QGRNSPAPAV-----TAASVTNIQATEVSVPQVNSSESG---	588
Mouse	DIDALCVAPRHVDRSDFTSFYDKLQEEVKDLRAVEAFVPMKLYSGVELDILFAR	172	Mouse	QGRNSPAPAV-----TAASVTNIQATEVSVPQVNSSESG---	588
Rat	DIDALCVAPRHVDRSDFTSFYDKLQEEVKDLRAVEAFVPMKLYSGVELDILFAR	172	Rat	QGRNSPAPAV-----TAASVTNIQATEVSVPQVNSSESG---	588
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	
Worm	LALKEVPDTELSDDNLLNLDQESVRSINGCRVAEOLLLVPRQKEFCVTLRAIKLNK	223	Worm	VEVSNVYVVEQRTKVVOEIVDLQADNGLNTSNGLEAEQKMEVPQSV-----	655
Fly	LALKEIPDDFDLDDNLLNLDQESVRSINGCRVTEILALVPHNIDFRLTLRAIKLNK	240	Fly	-----IDVVEQEPTQPHNNGNASSN-----TTTTEVACSKQPPTLHPHPHQOP	606
Human	LALQTIPEDDLDDNLLNLDQESVRSINGCRVTEILALVPHNIDFRLTLRAIKLNK	232	Human	-----GTSS-----ESIPQATQTP-----AISP	606
Mouse	LALQTIPEDDLDDNLLNLDQESVRSINGCRVTEILALVPHNIDFRLTLRAIKLNK	232	Mouse	-----GTSS-----ESIPQATQTP-----AISP	606
Rat	LALQTIPEDDLDDNLLNLDQESVRSINGCRVTEILALVPHNIDFRLTLRAIKLNK	232	Rat	-----GTSS-----ESIPQATQTP-----AISP	606
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	
Worm	RHGIYSNMGCFPGGIIWAILVARACQLYFNAASRLVHRMFIFSTWTVHPVLMENNN	283	Worm	-----PPAPQPPAHHHH---HQKTRNNNAAAAAASNSIFWGRSILHAASSLSAALSITGHKRR	731
Fly	RHGIYSNMGCFPGGIIWAILVARACQLYFNAASRLVHRMFIFSTWTVHPVLMENNN	300	Fly	PPKPTVSRVVSSTRLVNPFRSSGNAATSG--NA-----AT--KIPTIVGVKRT	652
Human	RHNIYSNMGCFPGGIIWAILVARACQLYFNAASRLVHRMFIFSTWTVHPVLMENNN	292	Human	PPKPTVSRVVSSTRLVNPFRSSGNAATSG--NA-----AT--KIPTIVGVKRT	652
Mouse	RHNIYSNMGCFPGGIIWAILVARACQLYFNAASRLVHRMFIFSTWTVHPVLMENNN	292	Mouse	PPKPTVSRVVSSTRLVNPFRSSGNAATSG--NA-----AT--KIPTIVGVKRT	652
Rat	RHNIYSNMGCFPGGIIWAILVARACQLYFNAASRLVHRMFIFSTWTVHPVLMENNN	292	Rat	PPKPTVSRVVSSTRLVNPFRSSGNAATSG--NA-----AT--KIPTIVGVKRT	652
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	
Worm	DRNDIPTLCRLVDPFRKNTDRFHVMPITPAPPEQNSTHNVTRSTATVKNICEALET	343	Worm	-----QQTATSTMISSNIAHSNYTQHSNHNNGGGGSHYKRTYYIDDDDEONNQPLTPNNQ	791
Fly	V-----NLRFQVDPFRVNASDRYHLMPIITPAYPQNSTHNVSESTKVVILTEPNRGNH	355	Fly	SSPHK-----EESPKTKTK-----EEQVDTET-----STTQ	679
Human	C-----NLMLPVDPFRVNPEDRYHLMPIITPAYPQNSTHNVSVSTRMVMVEFPKGLAI	347	Human	SSPNK-----EESPKTKTK-----EEQVDTET-----SAVQ	673
Mouse	C-----NLMLPVDPFRVNPEDRYHLMPIITPAYPQNSTHNVSVSTRMVMVEFPKGLAI	347	Mouse	SSPHK-----EESPKTKTK-----EEQVDTET-----SAVQ	673
Rat	C-----NLMLPVDPFRVNPEDRYHLMPIITPAYPQNSTHNVSVSTRMVMVEFPKGLAI	347	Rat	SSPHK-----EESPKTKTK-----EEQVDMET-----SAAP	673
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	
Worm	CRDISEGSKWTALFEFNFPSRYKHFIALMAADNEEKLNYGCFLESIRILVGSLEK	403	Worm	-----TQOQKAVRITA---TSASPATSVPAASAPAPTISL-----	827
Fly	TDEIHLGRIPWERLFEAFSPFYRYHFIIVLVNSQTADDLKLEWGLVESKIRILVGSLEK	415	Fly	SETVQASILLASQTSSTDLSDIP--ALPANPIPVIKNSIKILRLNR	718
Human	TDEIILSKAESKLFEPNFQYKHFIIVLASAPTEKQRLWGLVESKIRILVGSLEK	407	Human	SETVQASILLASQTSSTDLSDIP--ALPANPIPVIKNSIKILRLNR	718
Mouse	TDEIILSKAESKLFEPNFQYKHFIIVLASAPTEKQRLWGLVESKIRILVGSLEK	407	Mouse	SETVQASILLASQTSSTDLSDIP--ALPANPIPVIKNSIKILRLNR	718
Rat	TDEIILSKAESKLFEPNFQYKHFIIVLASAPTEKQRLWGLVESKIRILVGSLEK	407	Rat	SEAPASASLVASQTSSTDLSDIP--ALPANPIPVIKNSIKILRLNR	718
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	
Worm	NODIIAHNDPNKHKPSNAK-----DVPENKRVTVWFIGLE	443	Worm	-----	
Fly	NPHIALRVNPKCFEPKKGASNNQNSNEDDLKOSQGNQSAVTSAPFCNHWFIGLE	475	Fly	-----	
Human	NEFITLARVNPQSPFAPKESF-----DKEEFKTHWVIGLV	443	Human	-----	
Mouse	NEFITLARVNPQSPFAPKESF-----DKEEFKTHWVIGLV	443	Mouse	-----	
Rat	NEFITLARVNPQSPFAPKESF-----DKEEFKTHWVIGLV	443	Rat	-----	
	* : : * : : * : : * : : * : : * : : * : : * : : * : : * : : * : : *			* : : * : : * : : * : : * : : * : : * : : * : : * : : *	

SYMK-1 (Symplekin)

N		DUF3453	Symplekin C		C
Worm	MDYIQG-----LNEENETASERIGALKEARDAETIEKKLLSLSTAM	42	Worm	-FYKVLLETPLLTPNAIERLKQVCLAKE-NEHGMAMRELINTRNRQRPQLQFLGLFF	730
Fly	MSIIGRSQFVS-ETANLFTOEK-----TATARAKVDDWCHNELVIASP-STKCELLAKVQ	53	Fly	LIRRVLEAPLIPESVIGHLVQLSDDDEFSGHLEIKDLAVLRPPKRNRPVRLNLFV	718
Human	MASGSGDSVTRRSVASQFTQEEGPGIDGMTTSERVVDLLNQAAALITN-DSKITVLKQVQ	59	Human	-FTKVLEAPLITESALEVVRKYCEDERTYLGHTSLRDLIPKRPSPQFYLHVLLDLS	722
Mouse	MASGSGDSVTRRSVASQFTQEEGPGIDGMTTSERVVDLLNQAAALITN-DSKITVLKQVQ	59	Mouse	-FTKVLEAPLITESALEVVRKYCEDERTYLGHTSLRDLIPKRPSPQFYLHVLLDLS	722
Rat	MASGSGDSVTRRSVASQFTQEEGPGIDGMTTSERVVDLLNQAAALITN-DSKITVLKQVQ	59	Rat	-FTKVLEAPLITESALEVVRKYCEDERTYLGHTSLRDLIPKRPSPQFYLHVLLDLS	722
	* * * * *			* * * * *	
Worm	ELLIDPSLSISILONFITEMLEFAELMDSRILCLLVDFILKASAKDPTCNKTVERYSFY	102	Worm	MERPELRSSCLEVVKELCYLDF-IRSSLSQARMQINDCLESPPMYMRSS-----EDSD	784
Fly	ETVL---GSCAEAEELLESVLSLADSNMVRKQVAVFVQVCKVVELLPHVINVMGLI	111	Fly	HERLQDLAQAHVLSLVHVKILFARIDEFALEHLEIEQESPPAAVTSQDFGRPTPEP	778
Human	ELII---NKDPTLLDNFLDEIIAPQADKSIEVRKFVIGFIEACKRDIELLKLIANLMMI	117	Human	HEKDVRSQALLFIKRMYEKE-QLREYVEFALNVLQLLVHPNPPSVLFGADKDE-VAA	780
Mouse	ELII---NKDPTLLDNFLDEIIAPQADKSIEVRKFVIGFIEACKRDIELLKLIANLMMI	117	Mouse	HEKDVRSQALLFIKRMYEKE-QLREYVEFALNVLQLLVHPNPPSVLFGADKDE-VAA	780
Rat	ELII---NKDPTLLDNFLDEIIAPQADKSIEVRKFVIGFIEACKRDIELLKLIANLMMI	117	Rat	HEKDVRSQALLFIKRMYEKE-QLREYVEFALNVLQLLVHPNPPSVLFGADKDE-VAA	780
	* * * * *			* * * * *	
Worm	LIPWKSIRKVEGVIRKVVAVSTLPIVLEFA---IMDKHNAESCHDAFNLKSNICMLV	160	Worm	QWDEMYSKLVAVSTLPIVLEFA---LIPWKSIRKVEGVIRKVVAVSTLPIVLEFA	841
Fly	LRD---NSAQVIRKVEGVIRKVVAVSTLPIVLEFA---IMDKHNAESCHDAFNLKSNICMLV	166	Fly	QWDEMYSKLVAVSTLPIVLEFA---LIPWKSIRKVEGVIRKVVAVSTLPIVLEFA	841
Human	LRD---EMNVVVKKAILTMTQLYKVALQNMVSRVISELQEAQNMVSMAGDITILL	172	Human	PWTEETVQKCLYLYLALLPQNHK-LIHELAAVYTAIADIKRTVLVIEQPIRGGMNSP	839
Mouse	LRD---EMNVVVKKAILTMTQLYKVALQNMVSRVISELQEAQNMVSMAGDITILL	172	Mouse	PWTEETVQKCLYLYLALLPQNHK-LIHELAAVYTAIADIKRTVLVIEQPIRGGMNSP	839
Rat	LRD---EMNVVVKKAILTMTQLYKVALQNMVSRVISELQEAQNMVSMAGDITILL	172	Rat	PWTEETVQKCLYLYLALLPQNHK-LIHELAAVYTAIADIKRTVLVIEQPIRGGMNSP	839
	* * * * *			* * * * *	
Worm	SDDHGOVRTVYKLEALILQSPKRELATGSHISWAEANTRFNRIISLSDVPSRHAFI	220	Worm	MVSLIEDCPYGAETLVARLVLLTERIT-PTSDLIQKILHDERKMDIRALLPIIGL	900
Fly	DSNDGIRTHIAIKFVGLVITLSPMADE-----I-----PRQEHDSIDRIPRPHYI	223	Fly	ELLLVENCCKGAETLVTRCHSLTKQVP-PSPELVKRVYDLYKRLDQVDFLIPVNLGL	898
Human	DSNDGIRTHIAIKFVGLVITLSPMADE-----I-----PRQEHDSIDRIPRPHYI	223	Human	ELLLVENCCKGAETLVTRCHSLTKQVP-PSPELVKRVYDLYKRLDQVDFLIPVNLGL	898
Mouse	DSNDGIRTHIAIKFVGLVITLSPMADE-----I-----PRQEHDSIDRIPRPHYI	223	Mouse	ELLLVENCCKGAETLVTRCHSLTKQVP-PSPELVKRVYDLYKRLDQVDFLIPVNLGL	898
Rat	DSNDGIRTHIAIKFVGLVITLSPMADE-----I-----PRQEHDSIDRIPRPHYI	223	Rat	ELLLVENCCKGAETLVTRCHSLTKQVP-PSPELVKRVYDLYKRLDQVDFLIPVNLGL	898
	* * * * *			* * * * *	
Worm	SYHKTQEAEEFALLKOTTVAEATSONLITVIESLCMITRCPQWENALPRVFDVKA	280	Worm	EREVEVRLIPTTFIFRAEYQKSVNVLFRKLYTVRDPQ---TGNLVDFPIVIEVHKIEPKM	958
Fly	AREKLEQEGNNDILILQFHTGTHISSVNLIACTSSSLCTIANMRPIMFAG---VEAFQ	271	Fly	TRSELISVLPKILKNPFI---VVEVFNRLLOTQHEGNSALSPNLNGELLIAHNDISV	956
Human	QYVNLMEGRKAADVQLKFMVHPAISSNLTALGSLANIAQRPHMSEV---IQAYET	280	Human	EXKEVIALPKILKNPFI---VVEVFNRLLOTQHEGNSALSPNLNGELLIAHNDISV	956
Mouse	QYVNLMEGRKAADVQLKFMVHPAISSNLTALGSLANIAQRPHMSEV---IQAYET	280	Mouse	EXKEVIALPKILKNPFI---VVEVFNRLLOTQHEGNSALSPNLNGELLIAHNDISV	956
Rat	QYVNLMEGRKAADVQLKFMVHPAISSNLTALGSLANIAQRPHMSEV---IQAYET	280	Rat	EXKEVIALPKILKNPFI---VVEVFNRLLOTQHEGNSALSPNLNGELLIAHNDISV	956
	* * * * *			* * * * *	
Worm	LHSNVPPMLSGQGVFLKRSFKYNILRLFLKLPASVPLQKITTMLTNLGLASPREVQGS	340	Worm	DNEAELLVNNLEFLDFPALLKPTASQAIKAVFWENVPPLFHSLYLTHKFKTSEFV	1018
Fly	LNANLPPTLDSQVSVKRSKLMQQLTLKXNGAEFAFASITRGLMDV-LGSSSTNEIQKL	330	Fly	CDIKATVATSLCLAEADRLTYOEVLMQVLEVTPLTMMTITIOSLTYPLRANFV	1015
Human	LNANLPPTLAKQSVSVKRNKLMHLSVLKHPASLEFQAQITTLVD-LGTPQAEIARNM	339	Human	CDKSIKATNLCFAERNVYSEVLAVVQMLQESPLPMLMRTVIOSLTMYPLRGV	1016
Mouse	LNANLPPTLAKQSVSVKRNKLMHLSVLKHPASLEFQAQITTLVD-LGTPQAEIARNM	339	Mouse	CDKSIKATNLCFAERNVYSEVLAVVQMLQESPLPMLMRTVIOSLTMYPLRGV	1016
Rat	LNANLPPTLAKQSVSVKRNKLMHLSVLKHPASLEFQAQITTLVD-LGTPQAEIARNM	339	Rat	CDKSIKATNLCFAERNVYSEVLAVVQMLQESPLPMLMRTVIOSLTMYPLRGV	1016
	* * * * *			* * * * *	
Worm	PPELIQIAPPP---POHFAEPVAKRPKIQIFEDDDDDDEAGSPTSTV-NAKDARTE	397	Worm	ANLFYKTEKKMYQSDRWKQAFPCIKELKTKAYPAVITLS-----PEVEELKEVL	1072
Fly	PPMDKQEMARRKRLDENAAQSLAKRARLACE-QDDQOQRMELDTE-----LEROROK	384	Fly	MNLLRLILKQVWRQKVMF-GFLKTCVRLKPSQMLLHLHPFAQDVALQCPDLRAL	1074
Human	PPSKDTRKPRD-----SDSTL-KMKLEPNLGEDDEKDLFGPSGTSKASQISQGS	393	Human	MNLLRLILKQVWRQKVMF-GFLKTCVRLKPSQMLLHLHPFAQDVALQCPDLRAL	1074
Mouse	PPSKDTRKPRD-----SDSTL-KMKLEPNLGEDDEKDLFGPSGTSKASQISQGS	393	Mouse	MNLLRLILKQVWRQKVMF-GFLKTCVRLKPSQMLLHLHPFAQDVALQCPDLRAL	1074
Rat	PPSKDTRKPRD-----SDSTL-KMKLEPNLGEDDEKDLFGPSGTSKASQISQGS	393	Rat	MNLLRLILKQVWRQKVMF-GFLKTCVRLKPSQMLLHLHPFAQDVALQCPDLRAL	1074
	* * * * *			* * * * *	
Worm	AIDMTAKFI-MECLNHETVNNHILKISLYLTPSEMPAASGYTPIANAGTEPNRGLSEL	456	Worm	G-----DGIVAEFKIYSTLATQQK-----N-MDEKIKELHOKERENR-	1111
Fly	STRVNEFLAEFNPETVTVTLVLEFLPSLTPVTPQKFLQETPTIREMSIQQVTVNISRP	444	Fly	SEYAESNQDEPMNGSGITQOVLDSIGKSVQVDFVDSRGGVSAEHIKEKAPDSSEISV	1134
Human	OTDITAEFL-QPLTPDNVANHLISMVLPETMPASFOAIYTPVESAGTEAQIKHLARL	452	Human	LAHVSFTPH--QOAHIPNSINTILEASGQ-----EP-EAKKAPAGPLEEDD-	1120
Mouse	OTDITAEFL-QPLTPDNVANHLISMVLPETMPASFOAIYTPVESAGTEAQIKHLARL	452	Mouse	LAHVSFTPH--QOAHIPNSINTILEASGQ-----EP-EAKKAPAGPLEEDD-	1120
Rat	OTDITAEFL-QPLTPDNVANHLISMVLPETMPASFOAIYTPVESAGTEAQIKHLARL	452	Rat	LAHVSFTPH--QOAHIPNSINTILEASGQ-----EP-EAKKAPAGPLEEDD-	1120
	* * * * *			* * * * *	
Worm	MAVQNTNKEIGPGYEWLQQRKKEYEARNKARSEBGAIAQ-----TP	498	Worm	STVPLVTSVLPVPPFQSDNLQPLPGE-----ERDKRLREEKKEKEREK-RTRESGKRS	1140
Fly	FGDLSERKREKGAATPSRE---PPFRVVKVQAIESTLAME-VDEDA-----VQR	491	Fly	STVPLVTSVLPVPPFQSDNLQPLPGE-----ERDKRLREEKKEKEREK-RTRESGKRS	1140
Human	MATQMTAAGLFGVQGTQKKEEKEEVV-KPESVILKRLSVQQAISVVGSGTNSP	511	Human	-LEPLTA-----P-APAPFPDQILGLRLAQKALKRQLEEEQKQKFGTGAP	1177
Mouse	MATQMTAAGLFGVQGTQKKEEKEEVV-KPESVILKRLSVQQAISVVGSGTNSP	511	Mouse	-LEPLTA-----P-APAPFPDQILGLRLAQKALKRQLEEEQKQKFGTGAP	1177
Rat	MATQMTAAGLFGVQGTQKKEEKEEVV-KPESVILKRLSVQQAISVVGSGTNSP	511	Rat	-LEPLTA-----P-APAPFPDQILGLRLAQKALKRQLEEEQKQKFGTGAP	1177
	* * * * *			* * * * *	
Worm	IHEPN-MSNRVPAQVQSLQSE-INTLPIV---QAKKAFNLVEAVVFDKEAADMPFL	553	Worm	SRR-----	1143
Fly	LSEEFQKREKATKRLRETMERAGQVTEKMKERATKLQETKPLPNLKEKFLTD	551	Fly	SS-----SSPSFSAAPQPPREAHQFREGQECETPAIFISMDOSGLAETTLLOSSLE	1224
Human	LEEEVQAKRRPEPII-----PVTQRLAGAGKKIFRLSDVLPFLTAQVEAMKLG	564	Human	TSVSVSTPLVGPAAAGPTPAEVMYREKGFECTPAIFISMDOSGLAETTLLOSSLE	1233
Mouse	LEEEVQAKRRPEPII-----PVTQRLAGAGKKIFRLSDVLPFLTAQVEAMKLG	564	Mouse	TSVSVSTPLVGPAAAGPTPAEVMYREKGFECTPAIFISMDOSGLAETTLLOSSLE	1233
Rat	LEEEVQAKRRPEPII-----PVTQRLAGAGKKIFRLSDVLPFLTAQVEAMKLG	564	Rat	TSVSVSTPLVGPAAAGPTPAEVMYREKGFECTPAIFISMDOSGLAETTLLOSSLE	1233
	* * * * *			* * * * *	
Worm	AYESVLAQERRVAVGAGARMLYQKLVKLTTRFWEDCTPFEKLEIFVLADHKRNLDALL	613	Worm	-----	1143
Fly	AVRILNRSERKIGKGVSKRRKLVITIAATFPD---NVRYGIMEFIEDIKQIDLAFS	608	Fly	-----	1165
Human	AVKRILRAEKAVACSGAAQVRIKILASLVTFQDS---GLKAEVLSFILDVRLARLDLAF	621	Human	GLPLKETAAGGLTKEERSPOTLAPVGDAMKTPSPAEDAREPEAKGNS	1274
Mouse	AVKRILRAEKAVACSGAAQVRIKILASLVTFQDS---GLKAEVLSFILDVRLARLDLAF	621	Mouse	GLPLKETAAGGLTKEERSPOTLAPVGDAMKTPSPAEDAREPEAKGNS	1274
Rat	AVKRILRAEKAVACSGAAQVRIKILASLVTFQDS---GLKAEVLSFILDVRLARLDLAF	621	Rat	GLPLKETAAGGLTKEERSPOTLAPVGDAMKTPSPAEDAREPEAKGNS	1274
	* * * * *			* * * * *	
Worm	WLCELYAQVQYSCALFMKEHIAQGEQLTOAGRLDRYDQAMCKMLDAMERNMEKEAL-	672	Worm	-----	1143
Fly	WLFEYSILQCFTRHTYVK-----TENRPHAYNELLNLIFIGERCDHKDKII	658	Fly	-----	1165
Human	WLQYENAYLAAG-----SGSLDKYEDCLICLLSGLQEKFOQKDG-I	663	Human	GLPLKETAAGGLTKEERSPOTLAPVGDAMKTPSPAEDAREPEAKGNS	1274
Mouse	WLQYENAYLAAG-----SGSLDKYEDCLICLLSGLQEKFOQKDG-I	663	Mouse	GLPLKETAAGGLTKEERSPOTLAPVGDAMKTPSPAEDAREPEAKGNS	1274
Rat	WLQYENAYLAAG-----SGSLDKYEDCLICLLSGLQEKFOQKDG-I	663	Rat	GLPLKETAAGGLTKEERSPOTLAPVGDAMKTPSPAEDAREPEAKGNS	1274
	* * * * *			* * * * *	

Name	Experiment #	Eggs/Hatched	Lethality (%)
<i>cpsf-1</i> (CPSF1)	1	163/11	93.7
	2	238/5	97.9
	3	149/1	99.3
<i>cpsf-2</i> (CPSF2)	1	68/37	64.8
	2	178/28	86.4
	3	221/25	89.8
<i>cpsf-4</i> (CPSF4)	1	323/5	98.5
	2	699/17	97.6
	3	204/3	98.6
<i>cpf-1</i> (CST1)	1	251/76	76.8
	2	200/64	75.8
	3	185/25	88.1
<i>cpf-2</i> (CSTF2)	1	446/54	89.2
	2	138/14	90.8
	3	61/3	95.3
<i>cfim-1</i> (NUDT21)	1	249/23	91.5
	2	196/20	90.7
	3	154/2	98.7
<i>cfim-2</i> (CPSF6)	1	137/1	99.3
	2	282/27	91.3
	3	260/32	89.0
<i>symk-1</i> (Symplekin)	1	62/4	93.9
	2	19/4	82.6
	3	114/5	95.8
<i>rbpl-1</i> (RBBP6)	1	293/0	100
	2	344/0	100
	3	116/0	100
<i>pcf-11</i> (PCF11)	1	141/5	96.6
	2	105/0	100
	3	172/5	97.2
<i>clpf-1</i> (CLP1)	1	286/23	92.6
	2	289/18	94.1
	3	208/17	92.4
<i>pkc-3</i> (negative control)	1	5/0	100
	2	8/0	100
	3	18/1	94.7
	4	51/1	98.1
	5	3/0	100
	6	22/0	100
	7	53/0	100
	8	6/0	100
	9	13/0	100
	10	19/0	100
	11	5/0	100
	12	4/0	100

Supplemental Figure S2: Results of the RNAi experiments of the *C. elegans* CPC. Twelve genes for the members of the *C. elegans* CPC were knocked-down using RNAi. Clones/rows are color-coded as from Figure 1. The human orthologs of each gene are shown in parenthesis in the first column. For each RNAi experiment we use 15 worms, and the number of eggs unhatched vs hatched at the end of the experiment were counted. The percent lethality was consistently high across all tested clones. *pkc-3* RNAi was used as a negative RNAi control, since it is known to induce strong embryonic lethality.



Supplemental Figure S3: Bioinformatic Pipeline used in this study. The pipeline uses raw transcriptome datasets downloaded from the public repository SRA trace archive to extract and map 3'-UTR end clusters to the closest protein-coding genes in the correct orientation. The pipeline is divided in three large steps: A) Acquisition/Mapping, B) 3'-UTR cluster preparation and C) 3'-UTR isoforms mapping.

In the acquisition/mapping step, we used custom made Perl scripts to extract reads with 23 consecutive As at the 3'-end or 23 consecutive Ts at the 5'-end and then mapped these filtered reads to the WS250 version of the *C. elegans* genome (Bowtie 2). We then sorted and indexed the reads for visualization purposes.

In the 3'-UTR cluster preparation step, we extracted SAM reads with 100% match to the WS250 and used them to prepare a new bedGraph file (BEDTools). We then merged the reads and discarded the clusters with less than 5 reads. Restrictive parameters for cluster identification and 3'-UTR end mapping included the discard of clusters with an adenosine content of <35% downstream of its end.


Clusters were assigned to a mapped 3'-UTR end and attached to the closest gene with 2,000 nt in the same orientation. At the completion of these steps we performed the 3'-UTR isoform mapping step, which consists of the counting and assignment the total number of 3'-UTR isoforms to a given gene.

We discarded clusters with a density of less than 30% of the total number of reads.

A



n=27,264

mismatch (+/-)	stringent	raw
1	1,604	2,167
5	2,637	3,373
10	2,898	3,842
20	3,702	5,437


B

n=27,264

mismatch (+/-)	Mangone et al., 2010	Jan et al., 2011
1	930	285
5	1,717	989
10	2,229	1,664
20	3,436	3,106

**C**


Supplemental Figure S4: Comparison with Tourasse et al., 2017. We have downloaded the poly(A) sites mapped in Tourasse et al. and performed a comparison with the 3'-UTRs present in our 3'-UTRome v2. A) Top Panel: number of mapped poly(A) sites from Tourasse et al. that match our stringent and raw datasets within +/-1 nt, +/- 5 nt, +/- 10 nt or +/- 20 nt. Bottom Panel: number of poly(A) sites in common between Tourasse et al. and Mangone et al. and between Tourasse et al. and Jan et al. within +/-1nt, +/- 5nt, +/- 10nt or +/- 20nt. B) Bar chart showing the % of similarity of the two datasets in Panel A. C. Venn diagrams comparing the 3'-UTRs shared (+/- 20nt) between Tourasse et al., and the UTRome v1 (Mangone et al., - (green), this study (UTRome v2 - red), and Jan et al. (orange). We have used our unfiltered dataset to compare UTRome v2 with Tourasse et al.




Supplemental Figure S5: PAS site usage in genes with multiple 3'-UTR isoforms. A) In genes with only two 3'-UTR isoforms with a difference of at least 10 nt between isoforms, 373 pairs of isoforms had canonical PAS elements in both isoforms with an average of 246 nt difference between isoforms while 665 pairs had variant PAS elements in both isoforms with an average of 125 nt difference between them. In isoform pairs where the type of PAS element switches, 71% have a shorter isoform with a variant PAS element and a longer isoform with a canonical PAS element with an average of 209 nt between them while the remaining 29% have a canonical PAS element on the shorter isoform and a variant PAS element on the longer isoform with an average of 322 nt between them. B) In genes with three or more 3'-UTR isoforms, genes where the longest and the shortest isoform both have canonical PAS elements have an average of 163 nt between them while genes where the longest and the shortest isoforms both have variant PAS elements have an average of 211 nt between them. 72% of genes switch from a variant PAS elements in the short isoform to a canonical PAS element in the long isoform, with an average of 181 nt between them. 28% of genes have canonical PAS elements in the short isoforms and variant PAS elements in the long 3'-UTR isoform, with an average of 211 nt between the two.

A


Genes with 1 3'-UTR isoform and no canonical PAS element w/ RRYRRR motif (n=1,637)




Genes with 2+ 3'-UTR isoform and no canonical PAS element w/ RRYRRR motif (n=5,006)

**B**

Genes with 1 3'-UTR isoform with no RRYRRR motif



Genes with 2 3'-UTR isoforms with no RRYRRR motif






Supplemental Figure S6: Detection of the PAS element in genes lacking a canonical AAUAAA hexamer. A) We have searched for the most common RRYRRR motifs located within the last 30 nt in genes with 1 (top) or 2+ (bottom) 3'-UTR isoforms with no canonical PAS and with a detectable RRYRRR motif. The left chart shows the occurrences of the seven most common PAS elements identified in these groups, and the right logo shows the identified PAS motif. Apart from a slight increase in percentage of adenosines and guanosines in 3'-UTRs of genes with 2+ 3'-UTRs, both results are similar. The overwhelming majority of PAS conform with the AAU(G/A)AA with a tolerance of 1 nt purine-purine or pyrimidine-pyrimidine replacement. B) PAS site usage in genes with 1 or 2 3'-UTR isoforms with non canonical PAS and no RRYRRR motif. The pie chart shows the 10 most common hexamers located within 30 nt upstream of the the cleavage site. Right logo plot shows the nucleotide conservation of the intergenic region encompassing the cleavage site from -30 to +20 nt. Arrow marks the cleavage site. The buffer region and the PAS is marked.

Biological Process	1 3'-UTR isoform (n=8,537)			2 3'-UTR isoform (n=4,741)			3+ 3'-UTR isoform (n=1,530)		
	adj.Pval	nGenes	Pathways	adj.Pval	nGenes	Pathways	adj.Pval	nGenes	Pathways
	5.7e-28	165	phosphorus metabolic process	3.6e-20	135	single-organism metabolic process	2.3e-03	19	small molecule metabolic process
	7.2e-28	220	single-organism metabolic process	1.4e-13	38	immune response	2.3e-03	21	organonitrogen compound metabolic process
	2.5e-26	159	phosphate-containing compound metabolic process	1.4e-13	38	immune system process	2.3e-03	8	ribonucleoside monophosphate metabolic process
	8.7e-23	149	macromolecule modification	5.0e-13	63	oxidation-reduction process	2.3e-03	8	nucleoside monophosphate metabolic process
	1.3e-17	98	phosphorylation	8.7e-12	35	innate immune response	2.3e-03	11	innate immune response
	1.3e-16	130	cellular protein modification process	7.5e-11	82	phosphorus metabolic process	2.3e-03	11	immune response
	1.3e-16	130	protein modification process	4.0e-10	41	defense response			
	4.9e-16	164	cellular protein metabolic process	1.1e-09	78	phosphate-containing compound metabolic process			
Cellular Component	adj.Pval	nGenes	Pathways	adj.Pval	nGenes	Pathways	adj.Pval	nGenes	Pathways
	5.4e-28	122	cytoplasmic part	4.1e-17	73	cytoplasmic part	4.0e-07	25	organelle part
	6.1e-22	48	mitochondrion	9.9e-08	20	endoplasmic reticulum	6.0e-07	26	cytoplasmic part
	9.7e-22	102	organelle part	9.9e-08	50	organelle part	6.0e-07	8	mitochondrial inner membrane
	5.2e-18	89	intracellular organelle part	4.3e-07	21	mitochondrion	6.0e-07	10	mitochondrial part
	2.5e-15	73	non-membrane-bounded organelle	2.9e-06	43	intracellular organelle part	6.0e-07	8	organelle inner membrane
	2.5e-15	73	intracellular non-membrane-bounded organelle	2.9e-06	52	nucleus	6.0e-07	10	organelle envelope
	8.7e-13	29	mitochondrial part	3.4e-06	23	extracellular region	6.0e-07	9	mitochondrial envelope
	1.0e-12	94	nucleus	4.5e-05	23	endomembrane system	6.0e-07	10	envelope
	6.8e-12	40	membrane-enclosed lumen	1.9e-04	13	mitochondrial part	3.5e-06	11	mitochondrion
Molecular Component	adj.Pval	nGenes	Pathways	adj.Pval	nGenes	Pathways	adj.Pval	nGenes	Pathways
	4.2e-11	38	intracellular organelle lumen	1.9e-04	7	membrane raft	4.5e-06	8	mitochondrial membrane
	7.6e-64	231	transferase activity	2.4e-28	121	hydrolase activity	2.5e-09	39	nucleic acid binding
	4.2e-54	220	hydrolase activity	1.3e-27	117	transferase activity	3.5e-09	37	hydrolase activity
	4.1e-39	204	nucleotide binding	1.7e-16	56	oxidoreductase activity	5.3e-08	37	small molecule binding
	4.1e-39	204	nucleoside phosphate binding	2.2e-15	103	small molecule binding	2.0e-07	35	nucleotide binding
	2.6e-38	206	small molecule binding	4.6e-15	100	nucleotide binding	2.0e-07	35	nucleoside phosphate binding
	6.5e-38	195	anion binding	4.6e-15	100	nucleoside phosphate binding	1.1e-06	15	RNA binding
	4.4e-36	119	transferase activity, transferring phosphorus-containing groups	5.3e-15	59	transferase activity, transferring phosphorus-containing groups	6.0e-06	31	anion binding
	1.1e-29	163	ribonucleotide binding	1.7e-13	70	zinc ion binding	1.8e-04	26	carbohydrate derivative binding
1.7e-29	166	carbohydrate derivative binding	4.5e-12	76	transition metal ion binding	2.2e-04	21	zinc ion binding	
2.1e-29	160	purine nucleoside binding	5.7e-11	89	nucleic acid binding	3.5e-04	15	oxidoreductase activity	


Supplemental Figure S7: GO term analysis for genes with 1, 2 or 3 3'-UTR isoforms.

A


Genes with 1 3'-UTR isoform (stringent – cluster ≥ 100 reads)



Supplemental Figure S8: Detection of the 'UGUA' element in *C. elegans* 3'-UTRs. A) Logo plot of the transcript's region within the cleavage site in genes with only one 3'-UTR isoform and with a canonical or variant PAS element. B) Identification of the 'UGUA' motif (red) within 100 nt upstream of the cleavage site in genes with one or two 3'-UTR isoforms. C) Binned frequency distribution of the occurrences of the AAUAAA and UGUA elements in distal 3'-UTR isoforms as in the right heatmap in Panel B (green and red) vs. the occurrences of the UGUA motif in a randomly generated 3'-UTR dataset (blue) (n=785).






Supplemental Figure S9: Detection of enriched elements in *C. elegans* 3'-UTRs of genes with 2 3'-UTR isoforms (only distal) (n=785). These motifs have been detected using the meme suite (Bailey et al., 2015.)



Supplemental Figure S10: Nucleotide binding site of the human CPSF160-WDR33-CPSF30 complex. Ribbon representation of the cryo-EM structure of human CPSF160-WDR33-CPSF30 complex (PDB code: 6DNF) (Sun et al., 2018). The nucleotides of the bound RNA fragment do not show a specific interaction with either CPSF30 or WDR33. The interactions are mostly established by π - π ring stacking. Color gray shows the CPSF160, pink for WDR33, and light green for CPSF30. Sticks represent the RNA molecules bound with CPSF30 and WDR33. Surfaces in the inlets are for individual nucleotides.

A *M03A1.3* wt 3'-UTR

TGAAAGGACCTGCAGTGTGTTTGGGCGATTGGAGTATTCTTCTGCATTGCT
 GTTGCCTTGTCACTTCTTGTGCGTCAATGGATATAAAAAATGTATTAATTATT
 AATGGAATTTTGGAAATCTCATCTAATTTATTGATTTTATTGAATACGGGT
 AGTTTCTGATAATTACTTTGCATTGTAAAAAACAACTTTGTATGAATA
 AACATATTGAACATCTAAGTGCTTGCCTTTTTTTTAAACTCAACTTTGGTT
 GCGCATATCTTGGCTCTCTTTAGTTTTTTATTAAAAATGTCAACTACAGA

**B****C***M03A1.3* wt 3'UTR*M03A1.3* mut 3'UTR**Supplemental Figure S11: *In vivo* cleavage assay for *M03A1.3*.**





A) *M03A1.3* genomic region cloned downstream of the GFP reporter. Blue: terminal portion of the *M03A1.3* ORF. Green: STOP codon. Gray: 3'-UTR. Red: mutated terminal adenosine nucleotides. The transgenic worms expressing the *Pmyo-3::GFP::M03A1.3_3'-UTR* wt and mutant cassette are shown below.

B) At the completion of the experiment, we recovered the total RNA and performed RT-PCR experiments using a forward primer annealing within the GFP ORF and a reverse polydT primer with two anchors containing Invitrogen Gateway adapters. The resultant amplicons were then subcloned in gateway vectors and sequenced to detect the cleavage site. An example of resultant trace files is shown.

C) Examples of 10 clones identified in this study for *M03A1.3*. The removal of the terminal genomic adenosine nucleotide induces a cleavage site 3 nt upstream of the canonical cleavage site in three clones (arrows), which also contain a terminal adenosine nucleotide. The PAS element is boxed in blue color.

A**Y106G6H.9 wt 3'-UTR**

AGAGCCACGTGCACCTTCTATAAACATCCAAAAAACTAAATATATATTT
 TTTTGAAATGCAAACAACACTCCGCAGTTTGTGGAAAAACGAATTGGT
 CTACTTCTTCA^{TAA}AACATATGCGGTTCAATTGATACTTTTATTTCCATT
 GGAATTAAATTTAATGAATTGCTTCTTTAAATATTATTTCTATGCATCTG
 TTCTTCCTTTTGATTCTTCCATGAATATCTTTTTTTTATTGATCCTACAG
 GATCGTACAGGATCTTGTACACATAAGATATCTACATATTTAATAATGT
 TCACCTTTGTTTCTATTCTTCATGCCAATAAAGAGAAAGTTTAAT^ATTT
 TCT^AGTCTGGAATTTTATTTTAAAAAGCTGTCAACTGACAAATTATTG
 TCCACGACTTCGTCTGTTATTTTGTAGTAAATGTTAGATCGACAGT

**B****C****Y106G6H.9 wt 3'UTR****double mut 3'UTR****mut 3'UTRs****Supplemental Figure S12: *In vivo* cleavage assay for Y106G6H.9.**




A) Y106G6H.9 genomic region cloned downstream of the GFP reporter. Blue: terminal portion of the Y106G6H.9 ORF. Green: STOP codon. Gray: 3'-UTR. Red: mutated terminal adenosine nucleotides. Red Asterisk: position of the cryptic cleavage site (see below). The transgenic worms expressing the Pmyo-3::GFP::Y106G6H.9_3'-UTR wt and mutant cassette are shown below.

B) At the completion of the experiment we recovered the total RNA and performed RT-PCR experiments using a forward primer annealing within the GFP ORF and a reverse polydT primer with two anchors containing Invitrogen Gateway adapters. The resultant amplicons were then subcloned in gateway vectors and sequenced to detect the cleavage site. An example of resultant trace files is shown.

C) Examples of several clones identified in this study for Y106G6H.9. In the wt we were able to detect two classes of cleavage sites, both ending within 4 nt of each other with a terminal adenosine nucleotide. In the double mutant, the removal of the terminal genomic adenosine induces a cleavage skip in two clones (arrows). In one case (red arrow), the cleavage occurs 20 nt downstream of the PAS element. Two of the mutant clones also shown an occurrence of a new cryptic cleavage site 100 nt upstream of the natural site (red asterisks), which also contain a terminal adenosine nucleotide at their 3' end. The PAS element is boxed in blue color.

A *ges-1* wt 3'-UTR

TCCTAACTAATAGTGCCATGCATTTCGTCAAACAAGGACGAGCTGTAAAAAT
 GCAATAAATTTATGTATTTAATTGATTTTGAATAAATATACTTTTGCTAC
 AAAATCTTCGGCAAATGCTCATGCTCGATTTCTCCCGCCAATTGAGCACC
 TGTCAATTTATCTTGTCAATTTTCTGTACAAACACTTCTTGCCCCGACCA

**B****C***ges-1* wt 3'-UTR

	STOP	AATAAATATACTTTTGCTACAAATCTTCGGCAA
#1	AATAAATATACTTTTGCTGG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#2	AACAAATATACTTTTGCTAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#3	AATAAATATACTTTTGCTAG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#4	AATAAATATACCTTTTAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#5	AATAAATATACTTTTGCTAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#6	AATAAATATACTTTTGCT	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#7	AATAAATATACTTTTGCTACG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#8	AATAAATATACTTTTGCTG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#9	AATAAATATACTTTTGGA	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#10	AATAAATATACTTTTGCTAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa

ges-1 mut 3'-UTR

	STOP	AATAAATATACTTTTGCTTCTTCTTCGGCAA
#1	AATAAATATACTTTTGCT	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#2	AATAAATATACTTTTGCTAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#3	AATAAATATACTTTTGCTTC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#4	AATAAATATACCTTTTGCTTCCG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#5	AATAAATATACTTTTGCTAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#6	AATAAATATACTTTTGCTTCAC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#7	AATAAATATACTTTTGCTTCG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#8	AATAAATATACTTTTGCTGC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#9	AATAAATATACTTTTGCTCC	aaaaaaaaaaaaaaaaaaaaaaaaaaaa
#10	AATAAATATACTTTTGCTTG	aaaaaaaaaaaaaaaaaaaaaaaaaaaa

Supplemental Figure S13: *In vivo* cleavage assay for *ges-1*.

A) *ges-1* genomic region cloned downstream of the GFP reporter. Blue: terminal portion of the *ges-1* ORF. Green: STOP codon. Gray: 3'UTR. Red: mutated terminal adenosine nucleotides. The transgenic worms expressing the Pmyo-3::GFP::*ges-1*_3'-UTR wt and mutant cassette are shown below.

B) At the completion of the experiment we recovered the total RNA and performed RT-PCR experiments using a forward primer annealing within the GFP ORF and a reverse polydT primer with two anchors containing Invitrogen Gateway adapters. The resultant amplicons were then subcloned in gateway vectors and sequenced to detect the cleavage site. An example of resultant trace files is shown.

C) Examples of 10 clones identified in this study for *ges-1*. The removal of the terminal genomic adenosine nucleotide does not alter the cleavage site but makes it more variable. The PAS element is boxed in blue color.

A**GO Term: Biological Process**

adj.Pval	nGenes	Pathways
7.2e-05	7	oxidation-reduction process
5.9e-04	2	deoxyribonucleoside diphosphate metabolic process
1.7e-03	8	single-organism metabolic process

GO Term: Molecular Component

adj.Pval	nGenes	Pathways
1.2e-03	5	oxidoreductase activity

Functional Enrichment: Kegg

adj.Pval	nGenes	Pathways
1.7e-03	1	Pentose and glucuronate interconversions
1.7e-03	1	Fructose and mannose metabolism

B

miRNA	Sequence	Hits
miR-272	u <u>guaggca</u> uggguguuug	7
miR-2217a	c <u>agagugg</u> gcagucggugucgauc	6
miR-2217b	c <u>agagcgg</u> gcagucggugucaauc	6
miR-5553	u <u>caauggg</u> uagcacguggcaaga	6
miR-265	u <u>gagggag</u> gaaggguuguau	5
miR-34	a <u>ggcagug</u> ugguuagcugguug	5
miR-44	u <u>gacuaga</u> gacacauucagcu	5
miR-4935	g <u>ccggcga</u> gagagggaggagagcg	5
miR-795	u <u>gagguag</u> auugaucagcgagcuu	5
miR-8190	c <u>gggaaau</u> cgcuuuggaauccagga	5
miR-8194	a <u>ugcgccu</u> uuaaaaagguacgg	5
miR-1822	a <u>guuucuc</u> ugggaaagcuauccggc	4
miR-71	u <u>gaaagac</u> augggguagugagacg	4

Supplemental Figure S14: miRNA target analysis in genes with 2 3'-UTR isoforms which either gain or lose a miRNA binding site. A) GO Term analysis of genes with multiple 3'-UTRs which gain or lose a miRNA target as predicted using our miRanda 'stringent' dataset (n=132). B) Most common miRNAs, their sequences, and number of occurrences.

Additional Materials and Methods

Comparative analysis of *C. elegans* members of the CPC

We have downloaded the protein sequences of each known member of the human CPC and used BLAT algorithm to identify *C. elegans* genes with high homology to their human counterparts. We then performed a protein BLAST analysis using the tools available at the NCBI website to obtain the amino acid sequences for the fly, rat, and mouse orthologs. These amino acid sequences were then aligned using Clustal Omega Multiple Sequence Alignment with standard parameters. At the completion of the analysis, we used the Batch NCBI Conserved Domain Search (Batch CD-Search) against the database CDD- 52910 PSSMs using standard parameters to identify the conserved domains across the aligned protein sequences. We then used these results to populate the location of these elements within the alignment shown in **Supplemental Figure S1**. We were unable to identify the *C. elegans* homolog of the human gene CPSF7.

Plasmid DNA isolation, sequencing and visualization

All plasmids used in this study were prepared from cultures grown overnight in LB using the Wizard Plus SV Minipreps DNA Purification System (Promega) according to the manufacturer's instructions. DNA samples were sequenced with Sanger sequencing performed at the DNASU Sequencing Core Facility (The Biodesign Institute, ASU, Tempe, AZ).

RNAi experiments

RNAi experiments were performed in standard NGM agar containing 1mM IPTG and 50 µg/ml ampicillin. These plates were seeded with 75 µl of RNAi clone bacteria and allowed to induce for a minimum of 16 hours. 5 N2 *C. elegans* at the L1 stage were aliquoted for each RNAi clone tested. Three days after plating, the progeny was scored for embryonic lethality. Each RNAi experiment was performed in triplicate. The total number of hatched and not hatched eggs was the following: *cpsf-1(CPSF160)* n=567; *cpsf-2(CPSF100)* n=557; *cpsf-4(CPSF30)* n=1,251; *cpf-2(CstF64)* n= 716; *cpf-1(CstF50)* n=801; *cfim-1(CFIm25)* n=644; *cfim-2(CFIm68)* n=739; *symk-1(symplekin)* n=208; *tag-214(RBBP6)* n=753; *pcf-11(CPF11)* n=428; *clpf-1(CLP1)* n=841.

Mutagenesis of 3'-UTRs cleavage sites

The mutagenesis reactions to remove the adenosine nucleotides near the cleavage sites were carried out using the QuikChange Site-Directed Mutagenesis Kit (Agilent).

The mutagenesis DNA primers for the site mutation reactions are available in

Supplemental Table S2. Each mutagenesis reaction was followed by DNA digestion using Dpn-1 enzyme and transformed in Top10 competent cells (Thermo Fisher Scientific) in agar plates containing 20mg/µL of kanamycin. We validated the nucleotide mutation using Sanger sequencing approach. *Wild type* and mutant 3'-UTRs cloned in pDONR P2RP3 were then shuttled into destination vectors using the Gateway LR Clonase II Plus Enzyme Mix (Invitrogen, Carlsbad, CA). The finalized destination vectors contained the *C. elegans* pharynx promoter (Pmyo-2) in the first position, a GFP

sequence with a mutated STOP codon in the second position, and the *wt* or mutant 3'-UTRs used in this study in the third position. The resultant recombined constructs were then transformed in Top10 competent cells (Thermo Fisher Scientific) and plated on 10mg/μL ampicillin plates overnight. The success of the recombination reaction was confirmed using Sanger sequencing with the M13F DNA primer.

Preparation of transgenic worm lines

EG6699 strain worms were kindly provided by Christian Frokjaer-Jensen (Frokjaer-Jensen et al. 2008). These worm strains were maintained at 18°C on nematode growth media (NGM) agar plates and propagated on plates seeded with OP50-1 bacteria. To synchronize worms for injections, EG6699 worms were bleached with bleaching solution (1 M NaOH) four days before injections. Each construct was mixed with an injection master mix containing pCFJ601 (25 ng/μl), pgH8 (10 ng/μl), and pCFJ104 (5 ng/μl) vectors. Injection needles were loaded with the injection mixture and mounted to the Leica DMI300B microscope. The needle was pressurized with 22 psi through the FemtoJet (Eppendorf). Young adult EG6699 worms were picked onto an agarose pad covered with mineral oil on a glass coverslip. Injected worms were rescued onto an NGM plate and rinsed with M9 buffer. Two days post-injections, the F1 progeny were screened with a Leica DMI3000B microscope for both *unc-119* rescues and expression of the red fluorescence produced by the co-injection marker and then isolated onto individual plates. These worms were allowed to lay eggs, and then the F2 progeny was screened for fluorescence. Once 75% of the progeny on a single plate were transgenic, the strains were used for further experimentation.

Worm genotype validation

Populations obtained from single worms from each of the seven strains were lysed using worm lysis buffer (EDTA, 0.1 M Tris, 10% Triton-X, Proteinase K, 20% Tween 20). These worms were subjected to heating in a Bio-Rad T100 Thermal Cycler. To confirm that the mutated cleavage site was present in the injected strains, we used PCR approach using Platinum Taq polymerase (Invitrogen) with a forward DNA primer binding the beginning of the GFP sequence and 3'-UTR-specific reverse DNA primers. The PCR product was then sequenced using Sanger sequencing with a forward DNA primer binding to the GFP sequence present in the injected construct.

Detection of the 3'-UTR cleavage skipping

Total RNA was extracted from transgenic strains using the Direct-zol RNA MiniPrep Plus kit (RPI) according to the manufacturer's instructions. We tested approximately 10 independent *wt* and mutant clones for each 3'-UTR. Approximately 50 μ L of worm pellet was used for extraction. cDNA was synthesized using a reverse transcription reaction using Superscript II enzyme (Invitrogen). The first strand reaction was performed using a reverse poly dT DNA primer containing two anchors and the attB Gateway BP recombination element (Invitrogen). The second strand of the cDNA was synthesized using a PCR with HiFi taq polymerase (Thermo Fisher Scientific) and the forward DNA primer containing the pDONR P2RP3 Gateway element (Invitrogen), which binds to GFP and the same reverse poly dT DNA primer used in the first strand reaction. The BP Gateway kit (Invitrogen) was once again used to clone the cDNA which contains the

polyA tail into pDONR P2RP3. These constructs were then transfected into Top10 competent cells (Thermo Fisher Scientific) and plated on agar plates containing 20mg/ μ L of Kanamycin. About 8-10 colonies were then sequenced with Sanger sequencing using the M13F DNA primer to map the location of the cleavage site.

Updated miRanda Predictions

We downloaded a complete list of *C. elegans* miRNAs from miRBase (Griffiths-Jones et al. 2006) and the miRanda algorithm v3.3a (John et al. 2004) from the microrna.org website. We queried the 3'-UTRome v2 with the miRanda algorithm using both standard and stringent parameters. The stringent query used was '-strict -sc -1.2'. The standard query produced 58,330 putative miRNA targets; the stringent query produced 12,136 putative miRNA targets. Both these predictions are included in WormBase (Lee et al. 2018) as individual tracks.

Homology model building

Homology modeling was performed using SWISS_MODEL (Waterhouse et al. 2018) with a matched template of human CPSF160-WDR33-CPSF30 complex (PDB code: 6DNF) (Sun et al. 2018). The molecular graphics were prepared using the UCSF ChimeraX software (version 0.8) (Goddard et al. 2018).